Darin J. Weber Sells 84,103 Shares of ProKidney Corp. (NASDAQ:PROK) Stock

ProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber sold 84,103 shares of the company’s stock in a transaction on Friday, April 12th. The stock was sold at an average price of $1.73, for a total value of $145,498.19. Following the sale, the senior vice president now owns 189,670 shares of the company’s stock, valued at $328,129.10. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

ProKidney Trading Down 15.5 %

ProKidney stock opened at $2.40 on Friday. The company has a market capitalization of $550.43 million, a PE ratio of -4.21 and a beta of 1.08. ProKidney Corp. has a 12 month low of $1.12 and a 12 month high of $13.51. The stock has a 50-day moving average price of $1.59 and a two-hundred day moving average price of $1.81.

ProKidney (NASDAQ:PROK) last posted its earnings results on Thursday, March 21st. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.10. As a group, analysts predict that ProKidney Corp. will post -0.65 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PROK has been the subject of several recent analyst reports. Bank of America downgraded ProKidney from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Morgan Stanley initiated coverage on ProKidney in a research report on Thursday, March 7th. They set an “equal weight” rating and a $3.00 price objective for the company.

Institutional Investors Weigh In On ProKidney

Several institutional investors and hedge funds have recently made changes to their positions in PROK. Lazard Asset Management LLC acquired a new stake in shares of ProKidney in the second quarter valued at about $31,000. Tower Research Capital LLC TRC increased its stake in shares of ProKidney by 98.5% in the first quarter. Tower Research Capital LLC TRC now owns 4,456 shares of the company’s stock valued at $50,000 after buying an additional 2,211 shares during the period. Legal & General Group Plc acquired a new stake in shares of ProKidney in the fourth quarter valued at about $57,000. Ameritas Investment Partners Inc. acquired a new stake in shares of ProKidney in the second quarter valued at about $57,000. Finally, UBS Group AG increased its stake in shares of ProKidney by 97.5% in the first quarter. UBS Group AG now owns 5,209 shares of the company’s stock valued at $59,000 after buying an additional 2,571 shares during the period. Institutional investors and hedge funds own 51.59% of the company’s stock.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.